Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A - Wikidata - awgldk - TriplyDB

Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A

Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A

http://www.wikidata.org/entity/Q34526987

about

Will there ever be a universal Staphylococcus aureus vaccine?Detection of new methicillin-resistant Staphylococcus aureus clones containing the toxic shock syndrome toxin 1 gene responsible for hospital- and community-acquired infections in France.Synthesis and immunogenicity evaluation of Salmonella enterica serovar Paratyphi A O-specific polysaccharide conjugated to diphtheria toxoid.Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoid Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates Phenotypic and genotypic characterization of nosocomial Staphylococcus aureus isolates from trauma patients.Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model.Staphylococcus aureus strains that express serotype 5 or serotype 8 capsular polysaccharides differ in virulence.Effect of a trivalent vaccine against Staphylococcus aureus mastitis lymphocyte subpopulations, antibody production, and neutrophil phagocytosis Structural rationale for the modulation of abscess formation by Staphylococcus aureus capsular polysaccharides.Progress in the development of effective vaccines to prevent selected gram-positive bacterial infections.Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera.Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines.Preparation, characterization, and immunological properties in mice of Escherichia coli O157 O-specific polysaccharide-protein conjugate vaccines Availability of complement bound to Staphylococcus aureus to interact with membrane complement receptors influences efficiency of phagocytosis.Antibodies to Staphylococcus aureus serotype 8 capsular polysaccharide react with and protect against serotype 5 and 8 isolates Antibodies to capsular polysaccharides are not protective against experimental Staphylococcus aureus endocarditis.A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge.Cloning of type 8 capsule genes and analysis of gene clusters for the production of different capsular polysaccharides in Staphylococcus aureus.Molecular characterization and transcriptional analysis of type 8 capsule genes in Staphylococcus aureus Staphylococcus aureus capsular polysaccharides.Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial.Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates The potential economic value of a Staphylococcus aureus vaccine among hemodialysis patients.Natural antibodies in normal human serum inhibit Staphylococcus aureus capsular polysaccharide vaccine efficacy.An antidote for Staphylococcus aureus pneumonia?MsaB activates capsule production at the transcription level in Staphylococcus aureus.Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis.The Staphylococcus aureus polysaccharide capsule and Efb-dependent fibrinogen shield act in concert to protect against phagocytosis.Antigenic determinants of Staphylococcus aureus type 5 and type 8 capsular polysaccharide vaccines.Passive immunization with antiserum to a nontoxic alpha-toxin mutant from Staphylococcus aureus is protective in a murine model.Evaluation of serotypes 5 and 8 capsular polysaccharides in protection against Staphylococcus aureus in murine models of infection.Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus.CD4 T cell antigens from Staphylococcus aureus Newman strain identified following immunization with heat-killed bacteria.

P2860

Q26824837-89DE1823-B316-4438-8069-7B5855C16800 Q30353240-12E43E39-9DA8-486D-899C-6B917CBF371E Q33577920-0F1F5CA3-289D-457B-9A2A-7DF8A68FFCCF Q33607442-A2BC746A-B483-4F24-B2BE-B6B1FC291F0E Q33613531-32DB52F5-C82A-4097-BE41-65EB7EC66DC5 Q33656004-6D4A6CF4-E50B-4A59-9B42-7E1AEB4A1B1C Q33767412-E4B9A339-DD6C-410A-95F6-05C9FAC52393 Q33788238-A44E6A02-E73A-4743-BC70-FD1C44996060 Q33840647-B2A0A9B4-9DCF-406D-B298-CEED57D07A43 Q33931083-40A7DA3F-2305-4BE0-9FD9-4BC3AF2F113B Q34112608-6FC88B46-8884-4794-AD5E-25CA91F50746 Q34300720-C5ADBC94-A147-4730-86EB-E704DB5C9DF8 Q34541176-A1A32E71-78DD-4DF4-A1F3-76433478471D Q34545082-9364CA6B-2CCB-4FC1-B0D3-72E84345EDE5 Q34581644-83FDE2FD-5FA7-47E4-9BEA-8DB928D269F6 Q34595644-A09B1B5C-FF79-4517-AA9D-660C47AECE6A Q35382289-FC58FA7D-A64C-45A0-8A42-4C4B0359588A Q35489404-C88F7055-0828-4424-A9D3-D3D1203B7189 Q35605034-A0D5D89C-B006-4C34-96D1-B0BCD3DA719E Q35620548-15767E56-774F-4629-AAAA-4B14CA13A64D Q35630504-F1E4FC95-A6B7-4275-94A6-8D9E80216BD4 Q35887417-CA5D46BF-CB82-44FC-97D0-8DBE130A0EF8 Q35925379-0BA50E8B-F7C7-4658-8C46-B2E806E3709F Q36020705-58810D84-015F-4F0D-B66F-ECBA8C85F774 Q36486860-3851F982-6DA5-4799-8864-6360591331FF Q36502876-6D6DF56B-82CA-4F45-8698-A061B3478ABE Q36966028-2F903D21-61EB-473D-809F-1FBD60BEB01C Q37548140-7C456CA2-477A-4C1C-9104-52A2BBC115F4 Q38876259-69B89948-CD4C-486E-8877-7242D0D79A8A Q39573071-83B15BB8-6233-46EC-A1B9-B15B27884EE3 Q39824967-C66FAFB1-9E5E-463E-8216-277298E6BF89 Q40245675-BA57039B-10EF-498B-AE1B-ABA6A9BA1A07 Q41871463-808E6367-2A03-47F7-A1DD-8D785617C116 Q42109044-11BD978A-910E-4D2B-83E0-9EDF17165849

P2860

Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A

http://www.wikidata.org/entity/Q34526987

description

1993 nî lūn-bûn

@nan

1993 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

1993 թվականի մարտին հրատարակված գիտական հոդված

@hy

1993年の論文

@ja

1993年論文

@yue

1993年論文

@zh-hant

1993年論文

@zh-hk

1993年論文

@zh-mo

1993年論文

@zh-tw

1993年论文

@wuu

name

Laboratory and clinical evalua ...... inosa recombinant exoprotein A

@ast

Laboratory and clinical evalua ...... inosa recombinant exoprotein A

@en

Laboratory and clinical evalua ...... inosa recombinant exoprotein A

@nl

type

label

Laboratory and clinical evalua ...... inosa recombinant exoprotein A

@ast

Laboratory and clinical evalua ...... inosa recombinant exoprotein A

@en

Laboratory and clinical evalua ...... inosa recombinant exoprotein A

@nl

prefLabel

Laboratory and clinical evalua ...... inosa recombinant exoprotein A

@ast

Laboratory and clinical evalua ...... inosa recombinant exoprotein A

@en

Laboratory and clinical evalua ...... inosa recombinant exoprotein A

@nl

P1433

Q34526987-248F568E-6F13-4671-99B1-2A83C1479B1C

P1476

Q34526987-D206151A-EEB4-439F-BC42-72EB76EBE980

P2093

Q34526987-184835CD-6FBE-4B5F-8F7A-1881974B28C3

Q34526987-1CE6FFE6-27A4-42A3-8E3E-12B2BF8BF782

Q34526987-40AD1503-E210-4FEA-832E-F6351AA78556

Q34526987-5753CA73-AB9D-4EB5-81EC-1142C362921D

Q34526987-58A51952-7B34-45C4-8F70-3B602358E200

Q34526987-711EA274-9FEB-4269-9819-B11D4F2AA0FA

Q34526987-8976CC7B-762E-4154-8A92-C7A46287D212

Q34526987-A74E922F-2662-4BBE-B405-A263747489BE

Q34526987-DF37AFB6-CC9B-40D2-B5B4-4F67381AAFB1

Q34526987-DF6FB624-FE4F-4C0D-88CB-EF2E2425830A

P2860

Q34526987-0D7B6597-012A-477E-B0F9-F2477A862F15

Q34526987-168D5A67-9B95-490F-BAC5-86B99882C01C

Q34526987-1BEBF5E5-D468-42E3-AB77-1002160796B0

Q34526987-1C81E304-C020-4EF5-8981-E026D22B8262

Q34526987-1EBAD606-F7B0-46FC-8295-29DAB3803F92

Q34526987-2290043A-4DCF-4C0C-B6CA-440F64DB1728

Q34526987-2F855D9F-B019-445B-9F36-B6FC50DD4316

Q34526987-31AFB23E-3D92-4248-952A-E217B23C4F45

Q34526987-347AC7DB-E27C-4B6B-A9AC-36506186F828

Q34526987-3EFBEAFF-FDF8-48A2-A120-ABEC8188B54D

P304

Q34526987-CDB938A2-98FA-4A14-96EC-07016DB37261

P31

Q34526987-787B978E-B230-4CDB-8F40-ADF243C0F486

P407

Q34526987-79EC04AF-2349-4F2F-BCB4-6C37B67978EB

P433

Q34526987-F4A377AC-2E29-4977-A5F7-E381E8B72289

P478

Q34526987-E2E857F0-7A43-4688-92EE-2762ACC2AF2A

P577

Q34526987-935AC610-9077-4468-BB29-524FB6C57DD4

P698

Q34526987-83122CFC-0E2E-41C3-9ED6-BC86DD650878

P921

Q34526987-64188496-71CA-4DCB-B9A5-283CFA98BC5C

Q34526987-C6C9DCCF-877B-4197-B921-2EE6FF8242D6

P932

Q34526987-3877822D-293D-4AD4-9FFE-15B91FC3D69A

P1433

Infection and Immunity

P1476

Laboratory and clinical evalua ...... inosa recombinant exoprotein A

@en

P2093

Bryla DA

http://www.w3.org/2001/XMLSchema#string

Fattom A

http://www.w3.org/2001/XMLSchema#string

Fitzgerald D

http://www.w3.org/2001/XMLSchema#string

Karakawa WW

http://www.w3.org/2001/XMLSchema#string

Li X

http://www.w3.org/2001/XMLSchema#string

Pastan I

http://www.w3.org/2001/XMLSchema#string

Robbins JB

http://www.w3.org/2001/XMLSchema#string

Schneerson R

http://www.w3.org/2001/XMLSchema#string

Shiloach J

http://www.w3.org/2001/XMLSchema#string

Watson DC

http://www.w3.org/2001/XMLSchema#string

P2860

Studies on influenza in the pandemic of 1957-1958. II. Pulmonary complications of influenza.

Neutralizing antibody to Pseudomonas aeruginosa exotoxin in human sera: evidence for in vivo toxin production during infection.

Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates.

Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia: a study of 55 cases and review.

Exotoxin A of Pseudomonas aeruginosa: active, cloned toxin is secreted into the periplasmic space of Escherichia coli.

Exotoxin A of Pseudomonas aeruginosa: substitution of glutamic acid 553 with aspartic acid drastically reduces toxicity and enzymatic activity

Structural analysis of the surface polysaccharide of Staphylococcus aureus M

Lymphoproliferative activity of Pseudomonas exotoxin A is dependent on intracellular processing and is associated with the carboxyl-terminal portion.

Phagocytic killing of encapsulated and microencapsulated Staphylococcus aureus by human polymorphonuclear leukocytes.

Comparative immunogenicity of conjugates composed of the Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-succinimidyl-3-(2-pyridyldithio)propionate

P304

1023-1032

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P577

1993-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

8432585

http://www.w3.org/2001/XMLSchema#string

P921

polysaccharides

Pseudomonas aeruginosa

P932

302834

http://www.w3.org/2001/XMLSchema#string